MERGENCE of antibiotic resistance by pathogenic Salmonella ……spp. is a worldwide problem. Antibiotic combination was used as a clinical cure to solve the problem. Over one and a half years , one hundred gastroenteritis bacterial pathogens were collected from three Egyptian hospitals from fecal and blood sources. 58% Salmonella isolates were purified and identified using phenotyping and serotyping techniques. Out of the 58% Salmonella spp., 41.4% represented S. Typhimurium, 27.6% S. Enteritidis, 5.2% S. Typhi, 3.4 % S. Paratyphi A, 3.4 % S. Paratyphi B and 19.0% other Salmonella. A total of 36 (62%) out of 58 Salmonella spp. were fluroquinolone resistant by disk diffusion method. Resistance of five Salmonella strains to the fluroquinolone group was confirmed by MICs values. The level of these values was from 32 ->512 µg/ml, which is higher than those recommended by CLSI. Seventy-five combined microtitre checkerboards were performed on the five fluroquinolone multiresistant Salmonella strains to assess the potential for combination therapy. No antagonism was observed with any combination. Synergy and additivity were achieved with 41.4% and 58.6%, respectively. Time-kill synergy was more often seen at 24hr. There is 100%, 50% and 40% agreement between time-kill and checkerboard results for three Salmonella strains. Resistant Salmonella has increased in Egypt. Fluroquinolone combination with β-lactams (gentamycin, amikacin) and aminoglycosides (cefotaxime) were effective in the treatment of resistant Salmonella Typhimurium, Enteritidis and Typhi.
pathogenesis (Gordon, 2008) . Animals are the main reservoirs for NTS. The transmission of this microorganism occurs by the consumption of inadequately cooked or pasteurized foods of animal origin, including poultry, beef, fish, eggs, and dairy products. The incidence of human salmonellosis varies with geographic, socioeconomic and environmental factors (AL-Dawodi et al., 2012) .
Salmonellosis and typhoid fever remain important public health problems worldwide (Ayana & Surekha, 2008) . Although antibiotics are not usually recommended for Salmonella gastroenteritis, they are recommended for invasive Salmonella infections, such as septicemia and meningitis that are common in infants, elderly and immunocompromised patients. Up to a decade ago, in many countries, conventional 1 st -line antimicrobial agents, such as ampicillin, chloramphenicol, and sulfamethoxazole-trimethoprim, were the drugs of choice for the treatment of life-threatening Salmonella infections and still remain the main therapeutic drugs of choice in most African countries with poor resources. However, in the past two decades, isolation of multidrug-resistant Salmonella spp. has been reported from many parts of the world (Wedel et al., 2005) . So, fluoroquinolones have become the 1 st -line drugs for the treatment of lifethreatening salmonellosis and typhoid fever, but with treatment failures due to multidrug-resistant strains (Hakanen et al., 2001; Hirose et al., 2002; Baucheron et al., 2004 and Lunguya et al., 2013) . Treatment of the latter with combination therapy, using two or more antibacterial agents, has become commonplace (Rybak & McGrath, 1996) .
Two of the most widely used in vitro methodologies to assess drug-drug interactions are the checkerboard minimum inhibitory concentration (MIC) technique, yielding the fractional inhibitory concentration index (FICI) and timekill kinetics McGrath, 1996 and White et al., 1996) . The checkerboard MIC method is prone to error and by necessity, its results are often confirmed with the more dynamic interaction provided by the time-kill kinetic study format (Cappelletty & Jacqueline et al., 2005) . The present study evaluates the effect of two combinations; fluoroquinolone with βlactams and fluoroquinolone with aminoglycosides, against antibiotic resistant typhodial and non-typhodial clinical Salmonella isolates in Egypt.
Materials and Methods

Clinical sitting
Samples for the present study were obtained from July 2008 through December 2009 from microbiological laboratories of three government hospitals in Cairo. A total of one-hundred bacterial isolates; sixty from Abo El-Reesh Hospital for children, twenty-five from El-Hommiate Hospital and fifteen from El-Demerdash Hospital, were used in this study. Clinical isolates were collected from fecal and blood samples of patients with proven acute gastroenteritis, enteric fever, septicemia and bacteremia.
Purification and Identification of Salmonella isolates
The morphology of colonies was observed by optical microscope, a single colony of expected bacteria (according to cell morphology) was picked and inoculated to the fresh agar plates. The purified colonies were obtained by repeated streaking of the single colony on fresh agar plates and their morphology was recorded as the basis for classification.
Pure bacterial isolates were identified using microbiological standard methods; selective and differential media (Brenner & Farmer, 2004 and Thompson & Miller, 2003) . Confirmation of putative Salmonella isolates was performed by biochemical reaction and serological method using Salmonella O antisera polyvalent slide agglutination tests (Demka, Sejken, Co., LTD, Tokyo, Japan) ( Table 1 ). The pure isolates were also further grouped into serogroup A, serogroup B or serogroup D Salmonella by the use of slide agglutination tests for antiserum factors (O) then tested to flagella (H) antiserum phase I & II according to Kauffman-White serotyping scheme (Popoff & LeMinor, 1997 and Popoff, 2001) . 
Antimicrobial susceptibility testing
Fifty-eight Salmonella spp. were obtained from 100 isolates and were screened for resistance to antimicrobial agents by disc diffusion method on Mueller-Hinton agar using commercial antibiotic disks including the aminoglycosides group [gentamycin (GN) (10 µg) and amikacin (AK) (30 µg)], β-lactams group [ampicillin (AMP) (10 µg), ampicillin/sulbctam (SAM) (20 µg), amoxicillin/clavulinic acid (AMC) (30 µg), piperacillin (PRL) (100 µg), piperacillin/tazbactam (TZP) (110 µg), cefotaxime (CTX) (30 µg), ceftriaxone (CRO) (30 µg), ceftazidime (CAZ) (30 µg), cefepime (FEP) (30 µg), impenem (IMP) (10 µg), aztroname (ATM) (30 µg)], phenicols [chloramphenicol (C) (30 µg)], sulfadrugs group [sulfamethoxazoletrimethoprim (SXT) (25 µg)] and fluoroquinolones group [ nalidixic acid (NA) (30 µg), ciprofloxacin(CIP) (5 µg), levofloxacin (LEV) (5 µg), ofloxacin (OFX) (5 µg) & norfloxacin (NOR) (30 µg)] (Oxoid, UK). The break points used were according to the interpretative criteria recommended by Clinical and Laboratory Standards Institute (CLSI, 2008) .
Determination of minimum inhibitory concentrations (MICs)
Standard powder forms of ciprofloxacin, levofloxacin, ofloxacin (Eipico), cefotaxime (Aventis Pharma), ceftazidime (GlaxoSmithKline), cefepime (Bristol-Myers Squibb), amikacin (Bristol-Myers Squibb) and gentamycin (Schering-Plough) were used. The MICs of these antibiotics were determined by the broth microdilution method according to CLSI (2008) at concentration range 0.1-512 µg/ml for each drug immediately prior to testing. Mueller-Hinton broth (LAB M, USA) was used as the culture medium. Escherichia coli ATCC 25922 and Salmonella Typhimurium ATCC 14028 were used as control strains for evaluation of antibiotic potency.
Evaluation of antibiotics synergy
Two different methods were compared for the determination of synergy: checkerboard and time-kill method.
Checkerboard method
The dynamic checkerboard method was performed to evaluate the interaction of fluoroquinolones in combination with β-lactams and aminoglycosides, each at a time, against Salmonella isolates. The concentration range of each antibiotic combination ranged from 1/4 to 1/5 concentrations of MIC up to 2X MIC dilution. Organisms and antibiotic concentrations were prepared as described for the MIC determination using microtitre plates. To evaluate the effect of the combinations, the fractional inhibitory concentration (FIC) index was calculated for each antibiotic in each combination using the following formula:
FIC index= FIC A +FIC B where: FIC A = MIC of drug A in combination/MIC of drug A alone
FIC B = MIC of drug B in combination/MIC of drug B alone Synergy was defined as an FIC index of ≤ 0.5. Additive or indifferent was defined as an FIC index of > 0.5 but of ≤ 4.0. Antagonism was defined as an FIC index of > 4.0 (White et al., 1996 and Satish et al., 2005) .
Time-kill curve
Drug concentrations used for time-kill assays were based on three criteria: (i) Concentrations likely to produce synergy as seen in checkerboard testing; (ii) Concentrations those were not more than twice the MIC of each drug; (iii) Concentrations that were within clinically achievable serum levels for each drug Time-kill assays were performed in 10ml Mueller-Hinton broth (LAB M, USA). Each assay included a growth control tube with no antibiotic. The inoculum and antibiotic dilution were prepared as in MIC determination. For determination of viable counts, the surviving bacteria were counted after 0, 3, 6 and 24 hr postinoculation at 37 º C by sub-culturing 100 µl after serially dilution in saline solution (0.9%) onto Mueller-Hinton agar plates in duplicate. Total bacterial count (log 10 cfu/ml) was determined after 24 h of incubation at 37 º C. A bactericidal effect was defined as ≥ 3 log 10 cfu/ml decrease after 24 h of incubation compared to the size of the initial inoculum. Synergy was defined as a decrease in colony count of ≥ 2 log 10 cfu/ml with the combination compared to the count obtained with the most active single drug. Antagonism was defined as an increase in colony count of ≥ 2 log 10 cfu/ml with the combination compared to the count obtained with the most active single drug. Additive was defined as a change in colony count of < 10 fold decrease in viable count at 24 h with the combination compared to the count obtained with the most active single drug (Eliopoulos & Moellering, 1991; White et al., 1996 and Satish et al., 2005) .
Results
Distribution of Salmonella isolates
During this study a total of 100 bacterial samples from enteric infections, during 18 months, were purified and identified. Out of the 100 isolates, 58 % proved to be Salmonella by microscopy, selective and differential media and biochemical examination. Distribution of the 58 Salmonella isolates, were: 40 from Abo-El-Reesh Children Hospital, 15 from El-Hommiate Hospital and 3 from El-Demerdash Hospital. Out of the 58 Salmonella spp., 64% were from males and 36% were from females, so incidence of infection was higher in male than in female, also the incidence of Salmonella infection was higher in children (69%) than in adults (31%) and stool was a higher source of infection (81.1%) than blood (18.9%).
Identification of pure Salmonella isolates
Out of the 58 Salmonella isolates, 24 (41% ) were Salmonella enterica serovar Typhimurium, 16 (28 %) were Salmonella enterica serovar Enteritidis, 3 (5 %) were Salmonella enterica serovar Typhi, 2 (3 %) were Salmonella enterica serovar Paratyphi A, 2 (3 %) were Salmonella enterica serovar Paratyphi B and 11 (19%) were other serovar. The most common serotypes among Salmonella strains were the two non-typhodial, S. Typhimurium followed by S. Enteritidis.
Antimicrobial susceptibility testing
The antibiotic resistance incidence rate in Salmonella Typhimurium was higher than in S. Enteritidis followed by S. Typhi and S. Paratyphi A & B.
Out of the 58 Salmonella isolates, five multi-resistant Salmonella isolates were selected (Fig.1) , these strains showed resistance to most tested antibiotics especially the fluoroquinolone group where As presented in Table 2 , the MIC for the five multi-resistant Salmonella isolates was tested and the data showed that S. Typhimurium (54) was the most resistan, t with MICs ranging from 128-512 µg/ml; while S. Typhi (49) had the lowest MIC ranging from 16-128 µg/ml for tested antibiotics. The MIC of ciprofloxacin for S. Typhimurium (57 and 54) was 512 µg/ml followed by S.Enteritidis (22) with 256µg/ml then S. Typhimurium (7) with 64 µg/ml while S. Typhi (49) had the lowest MIC of 16 µg/ml. For the β-lactams group, the MICs were similarly high for all strains except S. Typhi (49) which had lower MICs than others. For the Aminoglycosides group, gentamycin had higher MICs than amikacin, except for S. Tm (57). Table 3 summarizes the results of the checkerboards. of the 75 checkerboards, 41.3% were found to be synergistic according to FIC index and 58.6% additive for the test strains. There was no antagonism reported for any combination (Fig. 2) . Six of 18 checkerboards were found synergic by ≥ 2 log 10 decrease in killing curve as compared to the most active drug in combination at 24 h. One of the boards was defined as synergy by these criteria at 3 h, also one combination at 6h. One of the boards at 3 and 6h was defined as synergy and also one at 3 and 24 h and 6 and 24 h were defined as synergy by these criteria against three resistant Salmonella isolates. Out of 18 checkerboards, twelve recorded synergic action as compared with the most active drug. Killing-curve for Salmonella isolates (no.7, 49 & 54) showed 100% (5/5), 50% (4/8) and 40% (2/5) agreement between the checkerboard and time-kill, respectively.
Combination of antibiotics
Time-kill results showed that ciprofloxacin combined with gentamycin for S.Typhi (49) and with cefotaxime for S. Typhimurium (7) achieved synergy action as represented in Fig. 5c and 3a .   Fig. 3. Killing assay of Salmonella Typhimurium (S. Tm no. 7) at 0, 3, 6, 24 h incubation time. a) Time kill assay of ciprofloxacin at 16µg/ml + cefotaxime at 128µg/ml. b) Time kill assay of ofloxacin at 16µg/ml + amikacin 32µg/ml and ofloxacin at 32µg/ml +cefotaxime at 128µg/ml. c) Time kill assay of levofloxacin at 16µg/ml + gentamycin at 128µg/ml and levofloxacin 16µg/ml + cefotaxime 128µg/ml.
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Salmonella Typhimurium (7) killing-curve combination of ofloxacin with amikacin and cefotaxime also levofloxacin with gentamycin and cefotaxime showed synergistic action (Fig. 3b & 3c) . Killing-curve for S. Typhimurium (54) (Fig. 4a,b,c) represented antagonism when levofloxacin was combined with amikacin, gentamycin, and cefotaxime while when ofloxacin was combined with amikacin and gentamycin they had synergy action with 40% agreement with checkerboard . Figure 5a to 5e show that synergistic action was achieved in combination of ciprofloxacin with amikacin and gentamycin, ofloxacin with amikacin and levofloxacin with cefotaxime for killing curve of S. Ty (49), while three time-kill showed additive reaction for ciprofloxacin with cefotaxime and ceftazidime and ciprofloxacin combined with cefepime had antagonism action. 
Discussion
Bacterial enteropathogens account for gastroenteritis infections observed worldwide with Salmonella being the principal cause. The majority of Salmonella isolates from Egyptian hospitals are of S. Typhimurium and S. Enteritidis as non-typhoidal Salmonella and S. Typhi and, S. Paratyphi A, B as typhodial. Hakanen et al. (2006) reported that the countries of origin of nontyphodial Salmonella infections are most commonly Thailand with 34% of isolates, Egypt with 31% of isolates and Spain with 25% of isolates. The present study revealed that incidence of Salmonella in Egypt from July 2008 through December 2009, increased to 58% due to absence of sanitary measures regarding food habits. Aktas et al. (2007) stated that in Istanbul, Turkey 63% of Salmonella spp. were identified as S. Enteritidis and 36% as S. Typhimurium.
Salmonella incidence in children is higher than in adults and stool was recorded as the main source of infection compared to blood source. Marimón et al. (2004) reported that 53% of Salmonella isolates come from children compared to 47% from adults and stool represents 81.9% of isolates.
Within this context, the increasing incidence of fluoroquinolone resistance in Salmonella spp. is of great concern. The resistance rate is higher among S. Typhimurium isolates (41.3%) compared with S. Enteritidis (27.5%). This result is in good agreement with previous data reported by Ricci & Piddock (2009) , who found that S. Typhimurium are generally more often resistant than S.Enteritidis but contrasts with data obtained by Marimón et al. (2004) , who stated that nalidixic acid resistance in S. Enteritidis was more frequent than in S. Typhimurium (18.1 versus 3.0%).
The MIC breakpoints for the fluoroquinolone used in the study are much higher than those recommended by CLSI (2008) and strains resistant to one fluoroquinolone prove to be resistant to all other fluoroquinolones. The present results are in agreement in resistance effect but higher in percentage with the results obtained by Rotimi et al. (2008) , who showed that the resistance rates in Kuwait and United Arab Emirates for ciprofloxacin are 1.2% and 0.8%. Yang et al. (2011) studied the resistance of 30 Salmonella isolates to seven antibiotics and found that all (i.e. 100%) are resistant to nalidixic acid while 96.7% were resistant to difloxacin, 93.3% were resistant to sarafloxacin, 73.3% were resistant to enrofloxacin, 66.7% were resistant to ciprofloxacin and gatifloxacin and 13.3% were resistant to levofloxacin.
The combination of fluoroquinolones with β-lactams is an attractive alternative to the classic combination of aminoglycosides and β-lactams antibiotics in the empiric treatment of serious infections (Maiche & Teerenhovi, 1991) . The combination of ciprofloxacin with βlactams antibiotic can be synergistic (Gould et al., 1997) .
Time-kill curve experiments are frequently used to assess the activity of antimicrobial combination in vitro; however, the numbers of antimicrobial combinations that can be tested are limited. Therefore, we used the dynamic checkerboard method as a screen to determine the pertinent antibiotic concentration to be tested by the time-kill curve (Jacqueline et al., 2005) .
In the treatment of enteric fever, gentamycin alone is avoided considering its low intracellular concentration and the survival of Salmonella inside macrophages, so gentamycin is used with fluoroquinolones derivatives. In this study gentamycin achieved synergistic action in combination with fluoroquinolones, these results are in line with Mandal et al. (2003) who show that ciprofloxacin in combination with gentamycin using the time-kill method has a 2.64 log 10 decrease in cfu/ml against one isolate.
From the β-lactams group, the third-generation cephalosporin (cefotaxime) retained high activity and continues to be an important agent treating enteric Salmonella species; therefore, cefotaxime is chosen for timekill synergy. Kim et al. (2010) stated that in combination therapy, ciprofloxacin with cefotaxime might be the treatment of choice for patients with typhoid fever; they confirm this by the time-kill technique. The combination of ciprofloxacin and cefotaxime against all three nalidixic acid resistant S. Typhi strains and one nalidixic acid-susceptible S. Typhi ATCC 9992 strain is significantly more effective in vitro in reducing bacterial counts by ≥ 3 log 10 cfu/ml at 24 h and shows synergistic effects (Kim et al., 2010) . Cefotaxime and ciprofloxacin in combination may be considered as an option for difficult-to-treat salmonellosis (Chang et al., 2006) .
The antagonism action achieved in the time-kill combination may be explained as follows: A large proportion of the bacterial population may be affected by antibiotic, with resultant death, but some cells may remain viable because: (i) They are in a different growth stage and less susceptible; (ii) The concentration of antibiotics is not sufficient to reach the intracellular levels required to effect the death of all the cells in the culture; or (iii) Resistance emerges. The same discrepancy has been encountered with P. aeruginosa as reported by Cappelletty & Rybak (1996) .
Conclusion
The fluoroquinolone resistant human Salmonella infections have markedly increased and to overcome this problem we used a combination therapy. Fluroquinolone combination with β-lactams (gentamycin, amikacin) and aminoglycosides (cefotaxime) were effective in the treatment of resistant Salmonella Typhimurium, S. Enteritidis and Typhi.
